Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Metastatic Breast Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 91Carboplatin 79Specimen Handling 76Magnetic Resonance Spectroscopy 64Pemetrexed 60Cisplatin 49durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32Radiotherapy 30Radiosurgery 30osimertinib 29Blood Specimen Collection 27Biopsy 26Gemcitabine 24Docetaxel 24Immunoglobulin G 23Standard of Care 22Disulfides 22Etoposide 21Drug Therapy 21Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × vistusertib × 1 year × Clear all
NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

University of Birmingham

Phase 2 Completed
423 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡